Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Slightly Bullish +25

FDA to Hold Review Meeting for Moderna's Flu Vaccine

🩺 The FDA has scheduled a public advisory committee meeting for June 18 to review Moderna's experimental flu vaccine, Mflusiva.

🔬 This gathering will feature independent scientific and public-health experts evaluating the vaccine's safety and effectiveness.

⏳ Moderna is awaiting regulatory approval to begin standalone distribution of this flu shot later this August.

🔄 The agency reversed a February rejection of Mflusiva after initial objections from then-acting FDA vaccines chief Vinay Prasad.

📉 Moderna's stock prices have dropped significantly due to declining demand for its pandemic-era Spikevax product.

🧬 Mflusiva will be the first influenza vaccine developed using mRNA technology, a format currently criticized by HHS Secretary Robert F. Kennedy Jr.

Bullish Signals
  • The FDA has scheduled a public advisory committee meeting for June 18 to review Moderna's experimental influenza vaccine, Mflusiva.
  • After an initial rejection in February due to objections from the vaccines chief, the agency pivoted and agreed to convene this scientific review.
  • Moderna is positioned to receive standalone flu shot approval later this August if the review is successful.
  • Mflusiva would be the first flu vaccine made with mRNA technology, offering a new technological platform for the company.
Risk Factors
  • Moderna's initial application for its standalone flu shot was rejected in February at the behest of Vinay Prasad, the FDA's vaccines chief, indicating significant regulatory hurdles ahead.
  • The proposed Mflusiva vaccine faces criticism from Health and Human Services Secretary Robert F. Kennedy Jr., who oversees the FDA and has publicly criticized mRNA technology.
  • Moderna's stock has already tumbled from pandemic-era highs due to falling demand for Spikevax, adding pressure before this new product launch.
  • The company is facing a critical dependency on regulatory approval later in August, with the upcoming June 18 advisory committee meeting being a potential bottleneck that could delay or jeopardize the timeline.
Full Analysis
The FDA scheduled a public advisory committee meeting for June 18 to review Moderna's experimental mRNA flu vaccine, Mflusiva, examining its safety and effectiveness before a potential approval later in August. This meeting follows an initial rejection of the application in February by former FDA vaccines chief Vinay Prasad, despite objections from agency career staff, after which the agency agreed to reconsider the product following discussions with the company. Approval could mark a significant milestone as Moderna's shot would be the first flu vaccine utilizing mRNA technology. Moderna is seeking this new growth avenue as its stock has declined significantly from pandemic-era highs due to falling demand for its Spikevax COVID-19 vaccine. The proposed Mflusiva vaccine faces scrutiny because it utilizes mRNA technology, which has been criticized by Health and Human Services Secretary Robert F. Kennedy Jr., who currently oversees the FDA. The upcoming review aims to determine if the standalone flu shot can help reignite growth for the biopharmaceutical company after its reliance on pandemic-era vaccines wanes.